STOCK TITAN

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
conferences

Immunic, Inc. (Nasdaq: IMUX) announces its participation in multiple scientific and investor conferences in September 2024. Key events include:

1. MS R&D Day on September 10, featuring discussions on vidofludimus calcium (IMU-838) for MS treatment.

2. 40th ECTRIMS Congress (Sept 18-20) with presentations on vidofludimus calcium's impact on MS.

3. DMDG 50th Open Meeting (Sept 2-4) showcasing pharmacokinetics study results of vidofludimus calcium.

4. 20th International Celiac Disease Symposium (Sept 5-7) presenting data on IMU-856 for celiac disease treatment.

5. 2024 Cantor Fitzgerald Global Healthcare Conference (Sept 17-19) featuring a fireside chat with CEO Daniel Vitt.

These events highlight Immunic's progress in developing treatments for chronic inflammatory and autoimmune diseases.

Immunic, Inc. (Nasdaq: IMUX) annuncia la sua partecipazione a diverse conferenze scientifiche e per investitori a settembre 2024. I principali eventi includono:

1. MS R&D Day il 10 settembre, con discussioni sul vidofludimus calcio (IMU-838) per il trattamento della sclerosi multipla.

2. 40° Congresso ECTRIMS (18-20 settembre) con presentazioni sull'impatto del vidofludimus calcio sulla sclerosi multipla.

3. DMDG 50° Incontro Aperto (2-4 settembre) che mostra i risultati dello studio sulla farmacocinetica del vidofludimus calcio.

4. 20° Simposio Internazionale sulla Malattia Celiaca (5-7 settembre) che presenta dati su IMU-856 per il trattamento della malattia celiaca.

5. Conferenza Globale sulla Salute di Cantor Fitzgerald 2024 (17-19 settembre) che include una conversazione informale con il CEO Daniel Vitt.

Questi eventi evidenziano i progressi di Immunic nello sviluppo di trattamenti per malattie infiammatorie croniche e autoimmuni.

Immunic, Inc. (Nasdaq: IMUX) anuncia su participación en múltiples conferencias científicas e inversores en septiembre de 2024. Los eventos clave incluyen:

1. Día de I+D de la EM el 10 de septiembre, con discusiones sobre el vidofludimus calcio (IMU-838) para el tratamiento de la esclerosis múltiple.

2. 40° Congreso ECTRIMS (18-20 de septiembre) con presentaciones sobre el impacto del vidofludimus calcio en la esclerosis múltiple.

3. 50° Reunión Abierta DMDG (2-4 de septiembre) exhibiendo los resultados del estudio de farmacocinética del vidofludimus calcio.

4. 20° Simposio Internacional sobre Enfermedad Celíaca (5-7 de septiembre) presentando datos sobre el IMU-856 para el tratamiento de la enfermedad celíaca.

5. Conferencia Global de Salud de Cantor Fitzgerald 2024 (17-19 de septiembre) con una charla informal con el CEO Daniel Vitt.

Estos eventos destacan el progreso de Immunic en el desarrollo de tratamientos para enfermedades autoinmunes e inflamatorias crónicas.

Immunic, Inc. (Nasdaq: IMUX)가 2024년 9월에 여러 과학 및 투자자 회의에 참여할 예정임을 발표했습니다. 주요 이벤트는 다음과 같습니다:

1. MS R&D Day 9월 10일, 다발성 경화증 치료를 위한 비도플루디무스 칼슘(IMU-838)에 대한 논의가 이루어집니다.

2. 제40회 ECTRIMS 학회 (9월 18-20일) 비도플루디무스 칼슘의 다발성 경화증에 대한 영향에 대한 발표가 있습니다.

3. DMDG 50th 공개 회의 (9월 2-4일) 비도플루디무스 칼슘의 약동학 연구 결과가 전시됩니다.

4. 제20회 국제 셀리악병 심포지엄 (9월 5-7일) 셀리악병 치료를 위한 IMU-856 데이터 발표.

5. 2024 Cantor Fitzgerald 글로벌 헬스케어 컨퍼런스 (9월 17-19일) CEO 다니엘 빗과의 파이어사이드 챗이 포함됩니다.

이러한 이벤트는 만성 염증 및 자가면역 질환 치료 개발에 대한 Immunic의 진행 상황을 강조합니다.

Immunic, Inc. (Nasdaq: IMUX) annonce sa participation à plusieurs conférences scientifiques et pour investisseurs en septembre 2024. Les événements clés comprennent :

1. Journée R&D sur la SEP le 10 septembre, avec des discussions sur le vidofludimus calcium (IMU-838) pour le traitement de la sclérose en plaques.

2. 40ème Congrès ECTRIMS (18-20 septembre) avec des présentations sur l'impact du vidofludimus calcium sur la sclérose en plaques.

3. 50ème Réunion Ouverte DMDG (2-4 septembre) présentant les résultats d'une étude de pharmacocinétique sur le vidofludimus calcium.

4. 20ème Symposium International sur la Maladie Cœliaque (5-7 septembre) présentant des données sur l'IMU-856 pour le traitement de la maladie cœliaque.

5. Conférence Mondiale de Santé 2024 de Cantor Fitzgerald (17-19 septembre) incluant une discussion informelle avec le PDG Daniel Vitt.

Ces événements mettent en avant les progrès d'Immunic dans le développement de traitements pour les maladies inflammatoires chroniques et auto-immunes.

Immunic, Inc. (Nasdaq: IMUX) gibt seine Teilnahme an mehreren wissenschaftlichen und Investorenkonferenzen im September 2024 bekannt. Zu den wichtigsten Veranstaltungen gehören:

1. MS R&D Tag am 10. September, mit Diskussionen über Vidofludimus Calcium (IMU-838) zur Behandlung von MS.

2. 40. ECTRIMS-Kongress (18.-20. September) mit Präsentationen über die Auswirkungen von Vidofludimus Calcium auf MS.

3. DMDG 50. Offenes Treffen (2.-4. September) mit Ergebnissen der Pharmakokinetikstudie zu Vidofludimus Calcium.

4. 20. Internationales Symposium zur Zöliakie (5.-7. September) mit Daten zu IMU-856 zur Behandlung von Zöliakie.

5. 2024 Cantor Fitzgerald Globale Gesundheitskonferenz (17.-19. September) mit einem Gespräch am Kamin mit CEO Daniel Vitt.

Diese Veranstaltungen unterstreichen die Fortschritte von Immunic bei der Entwicklung von Behandlungen für chronisch entzündliche und Autoimmunerkrankungen.

Positive
  • None.
Negative
  • None.

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September:

  • September 10: Immunic's MS R&D Day. Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer; Jason Tardio, M.B.A., Chief Operating Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, will be joined by two of the MS industry's renowned experts to discuss the MS landscape as well as Immunic's orally available lead-asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) and its potential to become the treatment of choice for both relapsing and progressive MS patients.
    • Date: Tuesday, September 10, 2024
    • Time: 10:30 am to 12:30 pm ET, followed by a networking lunch
    • Location: One Five One, 151 West 42nd Street, New York, NY 10036
    • Featured Experts:
      • Francesca Montarolo, Ph.D., Neuroscience Institute Cavalieri Ottolenghi (NICO) and University Hospital San Luigi Gonzaga of Orbassano, Turin, Italy
      • Amit Bar-Or, M.D., FRCPC, Melissa and Paul Anderson Distinguished Chair, Director, Center for Neuroinflammation and Experimental Therapeutics, Chief, Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania
    • To register, please RSVP by sending an email to: ir@imux.com.
  • September 18-20: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Members of Immunic's management, medical, clinical and preclinical teams will attend this conference in Copenhagen, Denmark. Data on vidofludimus calcium will be presented in an oral presentation and three ePosters. Additionally, the team will be available throughout the event at booth #60. All poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.

Oral Poster Presentation:

    • Title: Serum Neurofilament Changes in Progressive MS: Exploring the Impact of Vidofludimus Calcium by Age and Disability in the CALLIPER Study Interim Analysis
    • Presenting Author: Robert J. Fox, Staff Neurologist, Mellon Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
    • Poster Number: P753
    • Session Title: Poster Session 2
    • Session Date: Thursday, September 19, 2024
    • Session Time: 4:45 pm – 6:45 pm CEST

ePosters:

    • Title: Exploring the Potential of Vidofludimus Calcium to Reduce Fatigue in Multiple Sclerosis by Preventing Epstein-Barr Virus Reactivation
    • ePoster Number: P1119
    • Title: Vidofludimus Calcium Activity on NURR1 in Preclinical Models: A Potential Neuroprotective Function in Multiple Sclerosis
    • ePoster Number: P1410
    • Title: Vidofludimus Calcium Shows T Helper Cell Modulatory Effects in Murine Experimental Autoimmune Encephalomyelitis: One of the Potential Mode of Action Pathways for MS Treatment
    • ePoster Number: P1390
  • September 2-4: DMDG 50th Open Meeting 2024. Juliano R. Fonseca, Ph.D., Head of Preclinical Development at Immunic, will present data from Immunic's phase 1, open-label mass balance and pharmacokinetics study of vidofludimus calcium in a poster presentation at this meeting in York, United Kingdom.
    • Title: Mass Balance and ADME Properties of [14C]-IMU-838 Following Oral Administration to Healthy Male Subjects
    • The presentation and specific details regarding poster number and session will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations, once they are available.
  • September 5-7: 20th International Celiac Disease Symposium ICDS. Martina Wirth, Senior Manager Translational Pharmacology at Immunic, will present data from Immunic's phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a late-breaking poster presentation at this symposium in Sheffield, United Kingdom.
    • Title: First-In-Human Trial of IMU-856, an Orally Available Epigenetic Modulator of Barrier Function and Regeneration for the Treatment of Celiac Disease
    • The presentation and specific details regarding poster number and session will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations, once they are available.
  • September 17-19: 2024 Cantor Fitzgerald Global Healthcare Conference. Dr. Vitt will participate in a fireside chat at this conference in New York on Wednesday, September 18, 2024, at 3:05 pm ET. A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the UkraineRussia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information 

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@ksca.com

Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-host-multiple-sclerosis-rd-day-and-participate-in-scientific-and-investor-conferences-in-september-302232141.html

SOURCE Immunic, Inc.

FAQ

What is the main focus of Immunic's MS R&D Day on September 10, 2024?

Immunic's MS R&D Day on September 10, 2024, will focus on discussing the multiple sclerosis landscape and the potential of vidofludimus calcium (IMU-838) to become the treatment of choice for both relapsing and progressive MS patients.

What data will be presented at the 40th ECTRIMS Congress for Immunic's stock IMUX?

At the 40th ECTRIMS Congress, Immunic (IMUX) will present data on vidofludimus calcium, including an oral presentation on serum neurofilament changes in progressive MS and three ePosters on its potential to reduce fatigue, its activity on NURR1, and its T helper cell modulatory effects.

What will be presented at the DMDG 50th Open Meeting regarding Immunic's IMUX stock?

At the DMDG 50th Open Meeting, Immunic (IMUX) will present data from its phase 1, open-label mass balance and pharmacokinetics study of vidofludimus calcium in a poster titled 'Mass Balance and ADME Properties of [14C]-IMU-838 Following Oral Administration to Healthy Male Subjects'.

What information will Immunic (IMUX) share at the 20th International Celiac Disease Symposium in September 2024?

At the 20th International Celiac Disease Symposium, Immunic (IMUX) will present data from its phase 1b clinical trial of IMU-856, an orally available small molecule modulator targeting SIRT6, in patients with celiac disease.

When and where will Immunic's CEO participate in the 2024 Cantor Fitzgerald Global Healthcare Conference?

Immunic's CEO, Daniel Vitt, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference in New York on Wednesday, September 18, 2024, at 3:05 pm ET.

Immunic, Inc.

NASDAQ:IMUX

IMUX Rankings

IMUX Latest News

IMUX Stock Data

109.90M
89.15M
3.44%
65.02%
4.21%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK